RESULTS OF AN INTERVENTION IN PRESCRIPTION OF CONVENTIONAL RELEASE VERAPAMIL IN PATIENTS WITH HYPERTENSION IN COLOMBIA
Author(s)
Machado J, Machado-Duque M, Giraldo C
Universidad Tecnológica de Pereira, Pereira, Colombia
OBJECTIVES: Identify patients who were being treated for hypertension with conventional release verapamil (CRV), notify the responsible of health care about cardiovascular risk to which they are exposed and achieve a reduction in the number of patients who use it. METHODS: A quasi-experimental prospective before and after study without a control group was conducted in 7289 patients diagnosed with hypertension to be found in treatment with CRV, between October 1, 2012 and December 31, 2012 in 8 Colombian cities from a database for dispensing medicines. Socio-demographic and pharmacological variables were evaluated. A total of 108 educational interventions were performed for those responsible for health care, and evaluated within three months the proportion of suspension of the prescriptions of CRV. Multivariate analysis was performed using SPSS 22.0. RESULTS: The mean age of patients was 67.9±11.8 years (range: 26-96 years). 70.6% were men. Was obtained that discontinue treatment with CRV a total of 1922 patients (26.3% of users), distributed as follows: 1160 (60.4%) were the presentation of 120 mg, while 762 (39.6%) the 80 mg. The variable being treated in the city of Medellín (OR: 17.6; 95% CI: 11.949 to 25.924; p <0.001) was associated statistically significant with change of CRV by another antihypertensive. CONCLUSIONS: We found relative moderate adherence to recommendations about the proper use of CRV in hypertensive patients. Must be reinforced intervention programs that reduce inappropriate prescribing of potential risks to patients of insurance companies and cities where the change was not achieved.
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PCV101
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Formulary Development, Prescribing Behavior, Quality of Care Measurement
Disease
Cardiovascular Disorders